Alongside Medable’s digitally enabled clinical trials platform, the two companies say they will accelerate clinical development, increase access to clinical research and improve data quality.
The partnership, Medable and Pluto add, will ‘revolutionize’ the patient experience by providing patients with greater control and the ability to share their health data directly into clinical trials through a seamless integration.
All in the industry know that the success of a clinical trial depends on the ability to enroll a prespecified and representative number of study participants within a planned time frame. At the same time, the data that is collected need to be of a certain standard.
Many find however, that due to increasing protocol complexity, stricter inclusion and exclusion criteria as well as manual data capture, that clinical trials remain too slow and costly to help many patients – especially patients whose best potential treatment option is a trial.
Improving patient care
Joy Bhosai, Pluto Health’s CEO, and founder said: “Our partnership is primarily a win for patients, alongside other stakeholders, who will benefit from ongoing enhanced support.
“Pluto is passionate about improving patient care in communities and designing systems that deliver resources for patients to manage health needs over time, especially if they are going through a clinical trial as part of a care option. We are excited for what the future holds with Medable.”
Medable and Pluto Health say their combined technologies will streamline enrollment and retention efforts by supporting the patient experience while facilitating easier recruitment and monitoring. Patients, they say, will benefit from additional support that can optimize engagement along their care journey. Clinical research sites are able to increase productivity with a data-driven, digitized screening process; and trial sponsors will improve cost efficiency and speed study execution, they said.
In addition to patient enrollment, the Medable-Pluto Health partnership will make it easier for study teams to access relevant patient information and improve data quality as well as be able to facilitate long-term follow-up with patients after the trial. They will be able to opt-in to receive real-time notifications of medically relevant future clinical trial opportunities.
Reducing inefficiencies from trials
Medable CEO and co-founder Michelle Longmire added: “As a fellow female physician entrepreneur, I connected instantly with Joy and respect her company’s mission. Together, our organizations will leverage advanced technologies to reduce inefficiencies from trial execution and deliver better site and patient experiences while expanding access to clinical research to more patients when they need it most. Medable looks forward to a fruitful partnership with Pluto Health to help drive more life-saving therapies to patients faster.”
In today’s siloed healthcare environment, Medable and Pluto Health will work together to connect patients to all the right medical resources – from access to a clinical trial to getting medications delivered directly to their doors.
“There are many complications that can cause patients to get off-course in their care journey and the same is true for clinical trials. We aim to help patients navigate a path to better health care,” added Bhosai.
Pluto Health has helped monitor and close nearly 500,000 care gaps spanning from missing preventive health immunizations to assistance with colon cancer screenings.
Decentralized and hybrid trials
Medable’s software-as-a-service platform has been used in more than 300 decentralized and hybrid clinical trials in 60 countries, serving more than one million patients and research participants globally. The company says its customers have achieved impressive results with decentralized and hybrid trials – including 200 percent faster enrollment and 50 percent cost reductions.
A 2022 financial modeling of DCTs using industry benchmark and Medable data and conducted by the Tufts Center for the Study of Drug Development shows that, on average, decentralized trials can achieve net financial benefits ranging from five to 13 times for phase 2 and phase 3 trials, due to reduced trial timelines and other factors.
